Results 1 to 10 of about 7,079 (166)

Combination Therapy With Vigabatrin and Prednisolone Versus Vigabatrin Alone for Infantile Spasms

Annals of Clinical and Translational Neurology
Objective The study evaluated the effectiveness of combination therapy with vigabatrin and prednisolone versus vigabatrin alone for treating infantile epileptic spasms syndrome (IESS).
Kullasate Sakpichaisakul, Ravindra Arya   +1 more
exaly   +3 more sources

Dissolution and stability of vigabatrin powder in water, fruit juice, milk, and infant formula [PDF]

Epilepsy & Behavior Reports
The prescribing information for the antiseizure medication Vigadrone® (vigabatrin) Powder for Oral Solution advises only reconstituting the powder in water prior to administration and discarding unused solution.
Michelle Zachman, Lixin Gong, Lingling An, Mark B. Halvorsen   +3 more
doaj   +2 more sources

Symptomatic vigabatrin‐associated MRI toxicity is associated with simultaneous hormonal therapy among patients with infantile spasms

Epilepsia Open
Vigabatrin‐associated brain abnormalities on MRI (VABAM) are observed in approximately 20% of children who receive vigabatrin for treatment of infantile epileptic spasms syndrome.
Shaun Hussain, Hiroki Nariai
exaly   +2 more sources

The role of antioxidant and anti-inflammatory mechanisms in the protective effects of vigabatrin against ovarian ischemia-reperfusion injury in a rat model [PDF]

Journal of Ovarian Research
Background Exposure of ovarian tissue to ischaemia and subsequent reperfusion can result in oxidative and inflammatory damage. A decline in adenosine triphosphate (ATP) levels has the potential to initiate pathological processes and compromise ...
Elif Hizal, Esra Uyar, Eda Bingul, Betul Cicek, Özlem Demir, Renad Mammadov, Cengiz Sarigul, Cebrail Gursul, Halis Suleyman   +8 more
doaj   +2 more sources

Early neurodevelopmental outcomes in a child with tuberous sclerosis complex treated with everolimus and vigabatrin [PDF]

BMC Neurology
Objectives To report early neurodevelopmental outcomes in a child with Tuberous Sclerosis Complex (TSC) treated with everolimus and vigabatrin. Methods The authors report a five-year-old girl with Tuberous Sclerosis Complex who was initiated on ...
Sarah ML. Wilson, Megan Samuels, Luana Pimentel, Shelley Varnado, Claire Sartwell, Rosleen Mansour, Deborah Pearson, Hope Northrup, Mary Kay Koenig   +8 more
doaj   +2 more sources

Short Course and Early Switch of Vigabatrin for Infantile spasms [PDF]

Annals of Child Neurology, 2020
Purpose Vigabatrin has proven efficacy in the treatment of infantile spasms, but it carries the risk of irreversible visual field constriction. The incidence of vigabatrin-induced visual field constriction seems to depend on the extent of vigabatrin ...
Hye Won Ryu, Hunmin Kim, Byung Chan Lim, Hee Hwang, Jong-Hee Chae, Ji Eun Choi, Ki Joong Kim   +6 more
doaj   +1 more source

EVALUATION OF THE STABILITY OF VIGABATRIN IN HOSPITALAR EXTEMPORANEOUS FORMULATIONS

Drug Analytical Research, 2019
The aim of this study was to analyze the chemical stability of the anticonvulsant vigabatrin extemporaneous formulation from tablets in storage conditions of different temperatures and types of packaging used.
Marcio Vinicius Ayres, Sarah Chagas Campanharo, Elfrides Schapoval, Nathalie Ribeiro Wingert, Martin Steppe   +4 more
doaj   +9 more sources

Peripheral visual field defect of vigabatrin in pediatric epilepsy: A review

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023
Vigabatrin is the medication used for the treatment of infantile spasms and refractory complex partial seizures, but its usage has always been contradictory due to its effect on vision.
Umme Habeeba A. Pathan, Navapreetha Shetty, Safiya Anhar, Reshma Mayya   +3 more
doaj   +1 more source

Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol

Neurological Research and Practice, 2022
Background Nearly one in three unconscious cardiac arrest survivors experience post-anoxic status epilepticus (PASE). Historically, PASE has been deemed untreatable resulting in its exclusion from status epilepticus clinical trials.
Carolina B. Maciel, Fernanda J. P. Teixeira, Katie J. Dickinson, Jessica C. Spana, Lisa H. Merck, Alejandro A. Rabinstein, Robert Sergott, Guogen Shan, Guanhong Miao, Charles A. Peloquin, Katharina M. Busl, Lawrence J. Hirsch   +11 more
doaj   +1 more source

Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. [PDF]

PLoS ONE, 2013
Epilepsy is a common neurological disorder and cause of significant morbidity and mortality. Although antiseizure medication is the first-line treatment for epilepsy, currently available medications are ineffective in a significant percentage of patients
Bo Zhang, Sharon S McDaniel, Nicholas R Rensing, Michael Wong   +3 more
doaj   +1 more source